MedTrace Logo

Impact of Low Muscle Mass in HNC Treated With Immunotherapy

NCT04721184 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 120

Last updated 2021-01-22

No results posted yet for this study

Summary

The purpose of the study is to evaluate the baseline muscle mass as a predictive biomarker of treatment response in patients with recurrence or metastatic squamous cell carcinoma of the head and the neck (SCCHN) treated with immune checkpoint inhibitors (ICI)

Conditions

Sponsors & Collaborators

  • Department of Health, Generalitat de Catalunya

    collaborator OTHER_GOV

  • Institut Català d'Oncologia

    lead OTHER

Principal Investigators

  • Lorena Arribas · Institut Catlà d'Oncologia

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-01-20
Primary Completion
2023-11-30
Completion
2024-08-31

Countries

  • Spain

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04721184 on ClinicalTrials.gov